Neuland Laboratories Yönetim
Yönetim kriter kontrolleri 2/4
Neuland Laboratories CEO'su Davuluri Rao, Aug2013 tarihinde atandı, in görev süresi 11.25 yıldır. in toplam yıllık tazminatı ₹ 148.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 16.3% maaş ve 83.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.3% ine doğrudan sahiptir ve bu hisseler ₹ 6.81B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.2 yıl ve 9.5 yıldır.
Anahtar bilgiler
Davuluri Rao
İcra Kurulu Başkanı
₹148.3m
Toplam tazminat
| CEO maaş yüzdesi | 16.3% |
| CEO görev süresi | 11.3yrs |
| CEO sahipliği | 3.3% |
| Yönetim ortalama görev süresi | 4.2yrs |
| Yönetim Kurulu ortalama görev süresi | 9.5yrs |
Son yönetim güncellemeleri
Recent updates
Concerns Surrounding Neuland Laboratories' (NSE:NEULANDLAB) Performance
Nov 14
Neuland Laboratories Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 09Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Is Well Worth Watching
Nov 08After Leaping 27% Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Are Not Flying Under The Radar
Oct 17Neuland Laboratories Limited's (NSE:NEULANDLAB) Shares Climb 44% But Its Business Is Yet to Catch Up
Aug 22Is Now The Time To Put Neuland Laboratories (NSE:NEULANDLAB) On Your Watchlist?
Aug 02Neuland Laboratories' (NSE:NEULANDLAB) Dividend Will Be Increased To ₹14.00
Jul 12Optimistic Investors Push Neuland Laboratories Limited (NSE:NEULANDLAB) Shares Up 28% But Growth Is Lacking
Jul 02Neuland Laboratories' (NSE:NEULANDLAB) Upcoming Dividend Will Be Larger Than Last Year's
Jun 19Is Neuland Laboratories (NSE:NEULANDLAB) Using Too Much Debt?
Jun 12Neuland Laboratories (NSE:NEULANDLAB) Will Pay A Larger Dividend Than Last Year At ₹14.00
May 21There's Reason For Concern Over Neuland Laboratories Limited's (NSE:NEULANDLAB) Massive 25% Price Jump
Apr 19We Ran A Stock Scan For Earnings Growth And Neuland Laboratories (NSE:NEULANDLAB) Passed With Ease
Apr 15Subdued Growth No Barrier To Neuland Laboratories Limited (NSE:NEULANDLAB) With Shares Advancing 29%
Feb 17Revenue Beat: Neuland Laboratories Limited Exceeded Revenue Forecasts By 8.1% And Analysts Are Updating Their Estimates
Feb 12Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Jan 05The Neuland Laboratories Limited (NSE:NEULANDLAB) Analyst Just Boosted Their Forecasts By A Meaningful Amount
Nov 12Here's Why We Think Neuland Laboratories (NSE:NEULANDLAB) Might Deserve Your Attention Today
Oct 27Neuland Laboratories (NSE:NEULANDLAB) Seems To Use Debt Rather Sparingly
Aug 24Forecast: Analysts Think Neuland Laboratories Limited's (NSE:NEULANDLAB) Business Prospects Have Improved Drastically
Aug 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jul 05Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
Jun 21Neuland Laboratories (NSE:NEULANDLAB) Is Increasing Its Dividend To ₹10.00
May 14Should You Be Adding Neuland Laboratories (NSE:NEULANDLAB) To Your Watchlist Today?
May 12Here's Why Neuland Laboratories (NSE:NEULANDLAB) Can Manage Its Debt Responsibly
Aug 30I Built A List Of Growing Companies And Neuland Laboratories (NSE:NEULANDLAB) Made The Cut
Feb 23The Consensus EPS Estimates For Neuland Laboratories Limited (NSE:NEULANDLAB) Just Fell Dramatically
Feb 03CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹3b |
| Jun 30 2024 | n/a | n/a | ₹3b |
| Mar 31 2024 | ₹148m | ₹24m | ₹3b |
| Dec 31 2023 | n/a | n/a | ₹3b |
| Sep 30 2023 | n/a | n/a | ₹3b |
| Jun 30 2023 | n/a | n/a | ₹2b |
| Mar 31 2023 | ₹58m | ₹20m | ₹2b |
| Dec 31 2022 | n/a | n/a | ₹1b |
| Sep 30 2022 | n/a | n/a | ₹831m |
| Jun 30 2022 | n/a | n/a | ₹651m |
| Mar 31 2022 | ₹30m | ₹15m | ₹638m |
| Dec 31 2021 | n/a | n/a | ₹593m |
| Sep 30 2021 | n/a | n/a | ₹731m |
| Jun 30 2021 | n/a | n/a | ₹742m |
| Mar 31 2021 | ₹34m | ₹11m | ₹806m |
| Dec 31 2020 | n/a | n/a | ₹540m |
| Sep 30 2020 | n/a | n/a | ₹384m |
| Jun 30 2020 | n/a | n/a | ₹257m |
| Mar 31 2020 | ₹22m | ₹10m | ₹162m |
| Dec 31 2019 | n/a | n/a | ₹321m |
| Sep 30 2019 | n/a | n/a | ₹257m |
| Jun 30 2019 | n/a | n/a | ₹216m |
| Mar 31 2019 | ₹13m | ₹10m | ₹164m |
| Mar 31 2018 | ₹5m | ₹3m | ₹121m |
Tazminat ve Piyasa: Davuluri 'nin toplam tazminatı ($USD 1.76M ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 610.84K ).
Tazminat ve Kazançlar: Davuluri 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Davuluri Rao (49 yo)
11.3yrs
Görev süresi
₹148,300,000
Tazminat
Mr. Davuluri Sucheth Rao has been the Chief Executive Officer of Neuland Laboratories Limited since August 1, 2013, where Mr. Rao also served as its Chief Operating Officer. At Neuland, Sucheth has been re...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman & Chief Promoter and Member of Scientific Advisory Board | 40.8yrs | ₹148.50m | 26.37% ₹ 54.4b | |
| Vice Chairman & CEO | 11.3yrs | ₹148.30m | 3.3% ₹ 6.8b | |
| Vice Chairman & MD | 15.4yrs | ₹148.30m | 2.24% ₹ 4.6b | |
| Chief Financial Officer | 2yrs | Veri yok | Veri yok | |
| Chief Scientific Officer & Member of Scientific Advisory Board | less than a year | Veri yok | Veri yok | |
| Company Secretary & Compliance Officer | 12.8yrs | Veri yok | Veri yok | |
| Senior VP of Global Head Sales & BD | no data | Veri yok | Veri yok | |
| Chief Human Resources Officer | no data | Veri yok | Veri yok | |
| Senior Vice President of Global API Sales | no data | Veri yok | Veri yok | |
| Chief Procurement Officer | no data | ₹6.81m | Veri yok | |
| President of Business Development & Contract Manufacturing | no data | Veri yok | Veri yok | |
| Chief Quality Officer | less than a year | Veri yok | Veri yok |
4.2yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş
Deneyimli Yönetim: NEULANDLAB 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Executive Chairman & Chief Promoter and Member of Scientific Advisory Board | 40.8yrs | ₹148.50m | 26.37% ₹ 54.4b | |
| Vice Chairman & CEO | 21.3yrs | ₹148.30m | 3.3% ₹ 6.8b | |
| Vice Chairman & MD | 15.4yrs | ₹148.30m | 2.24% ₹ 4.6b | |
| Chief Scientific Officer & Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 2yrs | ₹2.90m | 0.00062% ₹ 1.3m | |
| Non-Executive Independent Director | 5.8yrs | ₹3.24m | Veri yok | |
| Independent Director | 1.3yrs | ₹2.82m | Veri yok | |
| Non-Executive Director & Member of Scientific Advisory Board | 15.1yrs | ₹2.85m | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Non-Executive Independent Director | 9.5yrs | ₹3.16m | Veri yok | |
| Independent Director | 1.3yrs | ₹2.82m | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok |
9.5yrs
Ortalama Görev Süresi
78yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: NEULANDLAB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.5 yıldır).